CURIS INC

Curis, Inc. announced a Special Meeting of stockholders to be held virtually on June 25, 2026, to vote on a proposal to amend its Restated Certificate of Incorporation. The amendment would effect a reverse stock split of its common stock, with a ratio ranging from 1-for-5 to 1-for-25, at the discretion of the Board of Directors. Stockholders will also vote on a proposal to adjourn the meeting if necessary to solicit further proxies.

Curis, Inc. held its Annual Meeting of Stockholders on May 19, 2026, where shareholders approved an amendment to the Company's Restated Certificate of Incorporation. This amendment significantly increases the number of authorized shares of capital stock from 288,757,150 to 572,514,300 and common stock from 283,757,150 to 567,514,300. Additionally, the Company filed a Certificate of Elimination to remove the designations for Series A and Series B Convertible Preferred Stock, returning these shares to authorized and unissued preferred stock status. Stockholders also elected two Class III directors, approved executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor.

Curis Inc. reported a net loss of $24.2 million for Q1 2026, significantly wider than the $10.6 million loss in Q1 2025. The company's management expressed substantial doubt about its ability to continue as a going concern within the next year, citing recurring losses and the need for significant additional capital. Despite raising $18.9 million through financing activities in the quarter, including a January 2026 PIPE financing, the company's cash and cash equivalents stood at $15.0 million as of March 31, 2026.

Curis, Inc. reported a net loss of $24.2 million, or $1.25 per share, for the first quarter of 2026, a significant increase from $10.6 million in Q1 2025, with no revenues due to the prior sale of Erivedge® royalties. The company provided business updates on its emavusertib clinical programs, including ongoing enrollment in the TakeAim Lymphoma trial for PCNSL and the recently initiated TakeAim CLL trial. Curis also announced upcoming milestones for clinical data and stated that its cash and cash equivalents of $15.0 million, combined with anticipated proceeds from warrant exercises, should fund operations into the second half of 2027.

Curis, Inc. received a Delist Determination Letter from Nasdaq on April 27, 2026, due to its common stock trading below the minimum $1.00 bid price requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company's securities are scheduled for delisting and suspension from the Nasdaq Capital Market on May 6, 2026, unless it timely appeals the decision. Curis plans to request a hearing, which will stay delisting actions, but there's no assurance of a successful appeal or continued listing.